12 Dec 2025 08:00
Episode 393: Antibody–Drug Conjugates in Metastatic Breast Cancer
"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer.
Music Credit: "Fireflies and Stardust" by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.
Episode Notes
- This episode is not eligible for NCPD.
- ONS Podcast™ episodes:
- Episode 391: Pharmacology 101: Antibody–Drug Conjugates
- Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer
- Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer
- Episode 350: Breast Cancer Treatment Considerations for Nurses
- Episode 303: Cancer Symptom Management Basics: Ocular Toxicities
- ONS Voice articles:
- ONS Voice drug reference sheets:
